<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688012</url>
  </required_header>
  <id_info>
    <org_study_id>SPC3649-201</org_study_id>
    <secondary_id>EudraCT nummer 2008-001012-20</secondary_id>
    <nct_id>NCT00688012</nct_id>
  </id_info>
  <brief_title>Safety Study of SPC3649 in Healthy Men</brief_title>
  <official_title>A Placebo-controlled, Double-blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled, double-blind, randomized, single dose, dose escalating trial in healthy
      men to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPC3649.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <enrollment>64</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC3649</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Volunteers

          -  BMI: 19-28 kg/m2

          -  No clinically significant disease/disorder

          -  Screening laboratory tests without clinically significant abnormalities, must agree to
             use condoms during intercourse for one week after study drug infusion

          -  Following receipt of verbal and written information about the study, the subject must
             provide signed informed consent before any study related activity is carried out.

        Exclusion Criteria:

          -  Heavy exercise within the past 7 days

          -  Alcohol intake&gt; 21 units weekly

          -  Regular smoker

          -  Received experimental drug within 30 days of study entry

          -  Planned participation in any experimental study during the study period

          -  HIV-Ab, HBsAg and/or HCV Ab positive

          -  History of specific allergy

          -  Current use of any drug or narcotics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PhaseOne Trials, Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Joan Drejer/Regulatory Manager</name_title>
    <organization>Santaris Pharma</organization>
  </responsible_party>
  <keyword>antisense</keyword>
  <keyword>microRna antagonist</keyword>
  <keyword>anti-miR-122</keyword>
  <keyword>Safety in healthy volunteers</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

